Tag Archive for: ASCO 2025
Retrospective Study On Real World Data: Sipuleucel-T Shows Encouraging Results in mCRPC
/0 Comments/in Retrospective studies/by MaxPhase 1/2 Results for MHB088C Antibody-Drug Conjugate for mCRCP
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMevrometostat Update: Phase 2 Clinical Trial Keeps Showing Promising Results
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxCOMRADE Phase 2 Trial Initial Results: Combination of Olaparib and Radium-223 Shows Promise in Extending Progression-Free Survival
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 22/2025 June 1, 2025
- QED-203 Moving Closer to Clinical Trials for mCRPC May 30, 2025
- Positive Results From Phase 3 Trial of CAN-2409 for Localized Prostate Cancer Led to RMAT Designation May 29, 2025
- UPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC May 29, 2025